Autoimmune Phenomena After Acute Stroke (ARIMIS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01082783|
Recruitment Status : Completed
First Posted : March 9, 2010
Last Update Posted : February 2, 2018
The damage of the brain parenchyma, as well as the stroke-induced dysfunction of the blood-brain-barrier can make previously hidden CNS antigens "visible", and can thus lead to the development of autoimmune mechanisms.
It seems plausible that stroke-associated immunodepression influences the development and the phenotype of these autoreactive immune responses.
This study will investigate whether cerebral ischemia leads to changes in the immune response, in particular to the development and/or proliferation of autoreactive effector T-cells and/or regulatory T-cells. Furthermore, the association between the severity and the phenotype of this autoimmune response and the clinical course, i.e. prognosis and mortality, will be investigated.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||28 participants|
|Official Title:||Autoimmune Phenomena After Acute Stroke - the Role of Stroke-induced Immunodepression|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||November 2011|
|patients with acute media infarct|
|controls with cardiovascular risks|
- autoantigen-specific T-cells in patients with acute media infarct [ Time Frame: within 36 h ]quantitative determination of autoantigen-specific T-cells in patients with acute media infarct
- leukocytes in patients with acute media infarct [ Time Frame: within 36 hours ]quantitative and qualitative analysis of leukocytes in patients with acute media infarct
- frequency and phenotype of CNS-autoreactive immune cells under the influence of immunodepression [ Time Frame: within 36 h, after day 3, 7, 90 and 180 ]
- clinical course, i.e. mortality and prognosis (measured by mod. Rankin Scale) [ Time Frame: after day 90 and 180 ]
- clinical course, i.e. mortality and prognosis (measured by Bartel Index) [ Time Frame: after day 90 and 180 ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01082783
|Charité - Universitätsmedizin Berlin|
|Berlin, Germany, 10117|
|Principal Investigator:||Andreas Meisel, MD||Charite University, Berlin, Germany|